TeamTalk: Improving Inter-professional Communication During Cancer Treatment

NCT ID: NCT07083674

Last Updated: 2026-01-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2027-09-23

Study Completion Date

2029-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study focuses on improving interprofessional communication during cancer treatment, through an individual and hospital system intervention, to improve provider outcomes, patient care, and, ultimately, survival for children with cancer in low-resource settings.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pediatric Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Parallel-arm, pilot cluster-randomized wait list-controlled trial to evaluate the intervention compared to control
Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention Group

This study includes an intervention development phase (Aim 2) during which the intervention content and delivery mechanisms will be finalized. We will implement the multilevel intervention developed in Aim 2. We anticipate this will consist of one instance of intervention at each hospital and we will develop a full intervention manual following Aim 2. Details regarding the intervention will be updated prior to participant enrollment in the trial.

Group Type EXPERIMENTAL

Multi-level communication intervention

Intervention Type BEHAVIORAL

The intervention will target multiple levels (provider, unit, hospital) and will respond to identified modifiable communication challenges. Aim 2 intervention mapping will finalize the specific intervention; we anticipate it will involve training and education of staff members and new unit protocols for communication.

Waitlist Control Group

The wait list control is a group that does not receive an intervention during the study period, serving as an untreated comparison during the study, although they later receive the intervention. This intervention will be delivered after the completion of the last data collection instance.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Multi-level communication intervention

The intervention will target multiple levels (provider, unit, hospital) and will respond to identified modifiable communication challenges. Aim 2 intervention mapping will finalize the specific intervention; we anticipate it will involve training and education of staff members and new unit protocols for communication.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hospitals identified as being in lowest quartile of communication quality, as defined by prior cross-sectional CritCom analysis and measured as the overall CritCom score.
* All Global Alliance hospitals providing childhood cancer care will be eligible to participate.
* Individual participants will be included if they care for hospitalized children with cancer at risk of deterioration.

Exclusion Criteria

* None
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

St. Jude Children's Research Hospital

OTHER

Sponsor Role collaborator

National Institutes of Health (NIH)

NIH

Sponsor Role collaborator

National Cancer Institute (NCI)

NIH

Sponsor Role collaborator

Washington University School of Medicine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sara Malone

Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Washington University in St. Louis

St Louis, Missouri, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sara Malone, LCSW, PhD

Role: CONTACT

‭(502) 797-0240‬

References

Explore related publications, articles, or registry entries linked to this study.

DEVELOPMENT OF A QUANTITATIVE MEASURE (CRITCOM) TO ASSESS THE QUALITY OF INTERDISCIPLINARY COMMUNICATION AROUND PATIENT DETERIORATION IN VARIABLY RESOURCED HOSPITALS

Reference Type BACKGROUND

Agulnik A, Graetz DE, Carothers BJ, Rivera J, Blakeney EA, Hayes S, Chaitan VL, Cabassa L, Goss CW, Luke DA, Malone S. Strategies to improve healthcare team communication structure and quality in resource-variable childhood cancer hospitals (TeamTalk): a study protocol. Implement Sci Commun. 2025 Nov 17;6(1):124. doi: 10.1186/s43058-025-00811-z.

Reference Type DERIVED
PMID: 41250257 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1R01CA287374

Identifier Type: NIH

Identifier Source: secondary_id

View Link

202503183

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.